Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $2.23B |
| Gross Profit (TTM) | $-1.56B |
| EBITDA | $-2.30B |
| Operating Margin | -131.10% |
| Return on Equity | -36.60% |
| Return on Assets | -13.10% |
| Revenue/Share (TTM) | $5.69 |
| Book Value | $18.66 |
| Price-to-Book | 2.98 |
| Price-to-Sales (TTM) | 9.95 |
| EV/Revenue | 8.24 |
| EV/EBITDA | 4.64 |
| Quarterly Earnings Growth (YoY) | -85.10% |
| Quarterly Revenue Growth (YoY) | 260.20% |
| Shares Outstanding | $396.79M |
| Float | $370.06M |
| % Insiders | 7.31% |
| % Institutions | 78.31% |
Volatility is currently contracting
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) enters a critical six-day stretch with Q2 earnings due July 31, and an FDA decision on its seasonal flu vaccine expected August 5.
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna is racing towards an important approval. But it may not move the stock higher.
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRNA and any ticker you trade — then tracks every position and per-strategy win rate.
